MX2016007533A - Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos. - Google Patents

Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.

Info

Publication number
MX2016007533A
MX2016007533A MX2016007533A MX2016007533A MX2016007533A MX 2016007533 A MX2016007533 A MX 2016007533A MX 2016007533 A MX2016007533 A MX 2016007533A MX 2016007533 A MX2016007533 A MX 2016007533A MX 2016007533 A MX2016007533 A MX 2016007533A
Authority
MX
Mexico
Prior art keywords
binding
methods
molecules
staphylococcal
phagocyte
Prior art date
Application number
MX2016007533A
Other languages
English (en)
Inventor
J Torres Victor
Whitaker Brian
J Brezski Randall
Strohl William
Chiu Mark
T Buckley Peter
Soring Keri
KINDER Michelle
Lynch Anthony
Original Assignee
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York filed Critical Univ New York
Publication of MX2016007533A publication Critical patent/MX2016007533A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

La presente invención se refiere generalmente a moléculas multi-específicas que se unen a varios factores de virulencia bacteriana, a métodos para producir estas moléculas de unión, y al uso de estas moléculas de unión para el tratamiento de infecciones bacterianas. En particular, las moléculas de unión comprenden al menos dos dominios de unión, preferentemente un anticuerpo o fragmento de anticuerpo y una estructura de soporte alternativa. El primer dominio de unión es capaz de unirse a una proteína de superficie estafilocócica glicosilada, preferiblemente una proteína que contiene SDR. El segundo dominio de unión es capaz de unirse a una leucotoxina estafilocócica, preferentemente LukAB, LukD o LukE. Estos compuestos de unión multi-específicos tienen actividad de eliminación contra estafilococos y, por lo tanto, se pueden usar en el tratamiento y/o mejora de una infección por Staphylococcus, incluyendo Staphylococcus aureus resistente a meticilina.
MX2016007533A 2013-12-09 2014-12-09 Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos. MX2016007533A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361913714P 2013-12-09 2013-12-09
PCT/US2014/069347 WO2015089073A2 (en) 2013-12-09 2014-12-09 Compositions and methods for phagocyte delivery of anti-staphylococcal agents

Publications (1)

Publication Number Publication Date
MX2016007533A true MX2016007533A (es) 2016-12-14

Family

ID=53371952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007533A MX2016007533A (es) 2013-12-09 2014-12-09 Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.

Country Status (10)

Country Link
US (2) US9644023B2 (es)
EP (1) EP3080161B1 (es)
JP (1) JP2017502002A (es)
KR (1) KR20160097294A (es)
CN (1) CN106459187A (es)
AU (1) AU2014363987A1 (es)
CA (1) CA2932819A1 (es)
IL (1) IL246020A0 (es)
MX (1) MX2016007533A (es)
WO (1) WO2015089073A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10053513B2 (en) * 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
EP3080161B1 (en) 2013-12-09 2021-03-24 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents
JP7019423B2 (ja) * 2015-05-06 2022-02-15 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原（ｐｓｍａ）二重特異性結合剤及びその使用
CA2985138A1 (en) * 2015-05-06 2016-11-10 Janssen Biotech, Inc. Prostate specific membrane antigen binding fibronectin type iii domains
WO2016197071A1 (en) 2015-06-05 2016-12-08 New York University Compositions and methods for anti-staphylococcal biologic agents
US10925932B2 (en) * 2016-06-03 2021-02-23 Janssen Biotech, Inc. Serum albumin-binding fibronectin type III domains
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
JP7104703B2 (ja) * 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ８ａ結合フィブロネクチンｉｉｉ型ドメイン
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
CN107224575B (zh) * 2017-03-06 2018-11-09 浙江海隆生物科技有限公司 奶牛金黄色葡萄球菌乳房炎亚单位疫苗的组合物及其制备方法和应用
US11078263B2 (en) 2017-08-25 2021-08-03 Janssen Biotech, Inc. Fc γ RIII binding fibronectin type III domains, their conjugates and multispecific molecules comprising them
KR20210035846A (ko) 2018-07-24 2021-04-01 메디뮨 엘엘씨 에스. 아우레우스 클럼핑 인자 A(ClFA)에 지향되는 항체
CN109206512B (zh) * 2018-08-22 2020-08-25 中国人民解放军东部战区疾病预防控制中心 抗金黄色葡萄球菌富丝氨酸重复蛋白SraP的抗体IgG及应用
CN114929750A (zh) * 2019-09-13 2022-08-19 芝加哥大学 用于治疗葡萄球菌感染的方法和组合物
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１結合フィブロネクチンｉｉｉ型ドメイン
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
AU2020405107A1 (en) * 2019-12-18 2022-07-14 Aro Biotherapeutics Company Serum albumin-binding fibronectin type III domains and uses thereof
CN111671910B (zh) * 2020-06-28 2022-04-26 兴盟生物医药(苏州)有限公司 一种抗葡萄球菌感染的联合抗体制剂
US11926669B2 (en) 2022-05-30 2024-03-12 Hanall Biopharma Co., Ltd. Anti-FcRn antibody or antigen binding fragment thereof with improved stability

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4124480B2 (ja) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
WO1998056915A2 (en) 1997-06-12 1998-12-17 Research Corporation Technologies, Inc. Artificial antibody polypeptides
EP1100811B1 (en) 1998-07-28 2007-07-04 The Regents Of The University Of California Nucleic acids encoding a g-protein coupled receptor involved in sensory transduction
AU762978B2 (en) * 1998-08-31 2003-07-10 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
ES2278463T3 (es) 1998-12-08 2007-08-01 Biovation Limited Metodo para reducir la inmunogenicidad de proteinas.
US6979446B2 (en) * 2001-01-26 2005-12-27 Inhibitex, Inc. Monoclonal antibodies to the ClfA protein and method of use in treating or preventing infections
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
JP5657862B2 (ja) 2005-07-28 2015-01-21 ノバルティス アーゲー Ｍ−ｃｓｆに対する抗体の使用
WO2007141274A2 (en) 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
HUE029622T2 (en) * 2010-04-30 2017-03-28 Janssen Biotech Inc Stabilized fibronectin preparations, processes and applications
WO2011140337A2 (en) * 2010-05-05 2011-11-10 New York University Staphylococcus aureus leukocidins, therapeutic compositions, and uses thereof
EP2500035A1 (en) 2011-03-15 2012-09-19 Icon Genetics GmbH Pharmaceutical formulation containing immunglobulin
CN103717234A (zh) * 2011-06-19 2014-04-09 纽约大学 治疗和预防金黄色葡萄球菌感染及相关病状的方法
MX358827B (es) 2011-09-27 2018-09-05 Janssen Biotech Inc Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas.
EP2773659A2 (en) * 2011-10-31 2014-09-10 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
EP2793944A4 (en) * 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
ES2546105T3 (es) * 2012-04-17 2015-09-18 Arsanis Biosciences Gmbh Anticuerpo de reacción cruzada contra Staphylococcus aureus
EP3080161B1 (en) 2013-12-09 2021-03-24 New York University Compositions and methods for phagocyte delivery of anti-staphylococcal agents

Also Published As

Publication number Publication date
KR20160097294A (ko) 2016-08-17
EP3080161B1 (en) 2021-03-24
WO2015089073A2 (en) 2015-06-18
AU2014363987A1 (en) 2016-06-30
EP3080161A2 (en) 2016-10-19
JP2017502002A (ja) 2017-01-19
US20170233461A1 (en) 2017-08-17
WO2015089073A3 (en) 2015-10-08
US10087243B2 (en) 2018-10-02
IL246020A0 (en) 2016-07-31
US9644023B2 (en) 2017-05-09
CA2932819A1 (en) 2015-06-18
US20150210756A1 (en) 2015-07-30
CN106459187A (zh) 2017-02-22
EP3080161A4 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
MX2016007533A (es) Composiciones y metodos para el suministro fagocitico de agentes anti-estafilococicos.
PH12018501429A1 (en) Compositions and methods for treating and preventing staphylococcus aureus infections
BR112015013123A2 (pt) inibidores de beta-lactamase
PH12017501646A1 (en) Antimicrobial compounds and methods of making and using the same
EA201890315A1 (ru) Молекулы антител, связывающие cd22
MX2023003418A (es) Moleculas multiespecificas de union a antigenos y usos de estas.
MX2016009898A (es) Tratamientos para acne resistente.
HK1220624A1 (zh) 抗微生物劑的組合物和製劑、它們的方法以及用於治療微生物感染的方法
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
WO2014151680A8 (en) Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
TW201613575A (en) Treatment of polybacterial infections
PH12016500207A1 (en) Anti-infective compounds
MY173518A (en) Antimicrobial compounds and methods of making and using the same
PH12016500453A1 (en) Antimicrobial compounds and methods of making and using the same
WO2013025834A3 (en) Compositions and methods related to antibodies to staphylococcal protein a
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
NZ630881A (en) Use of semaphorin-4d binding molecules for treatment of atherosclerosis
MX357938B (es) Metodos para tratar y prevenir infecciones por staphylococcus aureus y afecciones asociadas.
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
EA201591362A1 (ru) Соединения и способы лечения бактериальных инфекций
WO2017075188A3 (en) Methods of using anti-alpha toxin antibody
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
ZA202006612B (en) Antibacterial compounds
WO2015112895A3 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
MX2017012535A (es) Compuestos hetorociclicos novedosos y su uso en la prevencion o tratamiento de las infecciones bacterianas.